Skip to main content
SpringerLink
Log in

Botulinum Toxins

  • Chapter
Facial Rejuvenation

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carruthers JDA, Carruthers JA (1992) Treatment of glabellar frown lines with C. Botulinum exotoxin. J Dermatol Surg Oncol 18:17–21

    PubMed  CAS  Google Scholar 

  2. American Society for Aesthetic Plastic Surgery http://www.surgery.org/press/statistics/php. Accessed September 21, 2006

    Google Scholar 

  3. Cohen JL, Dayan SH (2006) Botulinum toxin type a in the treatment of dermatochalasis: an open-label, randomized, dose-comparison study. J Drugs Dermatol 5:596–601

    PubMed  Google Scholar 

  4. Carruthers J, Carruthers A, Zelichowska A (2000) The power of combined therapies: Botox® and ablative facial laser resurfacing. Am J Cosmet Surg 17:129–131

    Google Scholar 

  5. Brin MF, Binder W, Blitzer A, Schenroek L, Pogoda JM (2002) Botulinum type A Botox® for pain and headache. In: Brin MF, Hallett M, Jankovic J (eds) Scientific and Therapeutic Aspects of Botulinum Toxin. Lippincott Williams and Wilkins, Philadelphia, pp 233–250

    Google Scholar 

  6. Cohen JL, Solish N (2003) Treatment of hyperhidrosis with botulinum toxin. Facial Plast Surg Clin North Am 11:493–502

    Article  PubMed  Google Scholar 

  7. Solish N, Benohanian A, Kowalski JW; Canadian Dermatology Study Group on Health-Related Quality of Life in Primary Axillary Hyperhidrosis (2005) Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg 31:405–413

    Article  PubMed  CAS  Google Scholar 

  8. Liu HT, Tsai SK, Kao MC, Hu JS (2006) Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med 7:89–91

    Article  PubMed  Google Scholar 

  9. Charles Finn J, Cox SE, Earl ML (2003) Social implications of hyperfunctional facial lines. Dermatol Surg 29:450–455

    Article  PubMed  CAS  Google Scholar 

  10. Narurkar V, Cohen J, Flynn T, Hirsch R (2006) Analysis of complications by non-physicians in laser, light, RF devices, fillers and non-invasive procedures. Presented at the ASDS Annual Meeting, 29 October 2006, Palm Desert, California

    Google Scholar 

  11. Carruthers J, Carruthers A (2003) A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox®)and non-animal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative BTX-A. Dermatol Surg 29:802–809

    Article  PubMed  Google Scholar 

  12. Alam M, Dover JS, Klein AW, Arndt KA (2002) Botulinum A exotoxin for hyperfunctional facial lines: where not to inject. Arch Dermatol 138:1180–1185

    Article  PubMed  Google Scholar 

  13. Semchyshyn N, Senglemann RD (2003) Botulinum toxin treatment of perioral rhytids. Dermatol Surg 29:490–495

    Article  PubMed  Google Scholar 

  14. Rohrer TE, Beer K (2005) Background to Botulinum toxin. In: Carruthers A, Carruthers J (eds) Botulinum Toxin. Elsevier Saunders, Philadelphia, pp 9–17

    Google Scholar 

  15. Scott AB (2004) Development of botulinum therapy. Dermatol Clin 22:131–133

    Article  PubMed  Google Scholar 

  16. Blitzer A, Brin MF, Keen MS, Aviv JE (1993) Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 119:1018–1022

    PubMed  CAS  Google Scholar 

  17. Alam M, Dover JS, Arndt KA (2002) Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 138:510–514

    Article  PubMed  CAS  Google Scholar 

  18. Goodman G (2003) Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis. Dermatol Surg 29:533–538

    Article  PubMed  Google Scholar 

  19. Hsu, TS, Dover JS, Arndt KA (2004) Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 140:1351–1354

    Article  PubMed  CAS  Google Scholar 

  20. Carruthers A, Carruthers J, Said S (2005) Doseranging study of botulinum toxin type A in the treatment of glabellar rhytides in females. Dermatol Surg 31:414–422

    Article  PubMed  CAS  Google Scholar 

  21. Flynn T, Carruthers JA, Carruthers A, Clark R (2003) Botulinum A toxin (Botox®) in the lower eyelid: dose-finding study. Dermatol Surg 29:943–950

    Article  PubMed  Google Scholar 

  22. Carruthers A, Carruthers J, Cohen J (2007) Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Dermatol Surg 33:S97–104

    Article  PubMed  CAS  Google Scholar 

  23. Cohen J, Hirsch R (2006) Challenge: correcting a downturned smile. Skin Aging 2:52

    Google Scholar 

  24. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM (2005) Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53:407–415

    Article  PubMed  Google Scholar 

  25. Klein AW (2003) Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg 29:549–556

    Article  PubMed  Google Scholar 

  26. Moore P, Naumann M (2003) General and clinical aspects of treatment with botulinum toxin. In: Moore P, Naumann M (eds) Handbook of Botulinum Toxin Treatment, 2nd edn. Blackwell Science, Oxford, pp 28–75

    Google Scholar 

  27. Carruthers J, Fagien S, Matarasso S, for the Botox Consensus Group (2004) Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 114:1S–22S

    Article  PubMed  Google Scholar 

  28. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N; Botox® Glabellar Lines I Study Group (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46:840–849

    Article  PubMed  Google Scholar 

  29. Glaich A, Cohen J, Goldberg L (2006) Achieving a lateral brow lift with botulinum toxin type A. J Cosmet Dermatol 19:121–123

    Google Scholar 

  30. Carruthers A, Carruthers J, Cohen J (2003) A prospective, double-blind, randomized, parallel group, dose-ranging study of Botoxin® in female subjects with horizontal forehead rhytides. Dermatol Surg 2003;29:462–467

    Google Scholar 

  31. Kane M (2003) Classification of crow’s feet patterns among Caucasian women: the key to individualizing treatment. Plast Reconstr Surg 112:33S–39S

    Article  PubMed  Google Scholar 

  32. Flynn TC, Carruthers JA, Carruthers JA, Clark RE II (2003) Botulinum A toxin (Botox®) in the lower eyelid: dose-finding study. Dermatol Surg 29:943–951

    Article  PubMed  Google Scholar 

  33. Goldman M (2003) Festoon formation after infraorbital botulinum A toxin: a case report. Dermatol Surg 29:560–561

    Article  PubMed  Google Scholar 

  34. Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N; Botox® Facial Aesthetics Study Team (2005) Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet. Dermatol Surg 31:257–262

    Article  PubMed  CAS  Google Scholar 

  35. Cohen J, Hirsch R (2006) Surgical insights: challenge: correcting low-lying brows. Skin Aging 14:30–31

    Google Scholar 

  36. Carruthers J, Carruthers A (2001) Botox® use in the mid and lower face and neck. Semin Cutan Med Surg 20:85–92

    Article  PubMed  CAS  Google Scholar 

  37. Tamura BM, Odo MY, Chang B, Cuce LC, Flynn TC (2005) Treatment of nasal wrinkles with botulinum toxin. Dermatol Surg 231:271–275

    Google Scholar 

  38. Beer K, Yohn M, Closter J (2005) A double-blinded, placebo-controlled study of Botox® for the treatment of subjects with chin rhytids. J Drugs Dermatol 4:417–422

    PubMed  Google Scholar 

  39. Kane MA (2003) The effect of botulinum toxin injections on the nasolabial fold. Plast Reconstr Surg 112:S66–72

    Article  Google Scholar 

  40. Carruthers J, Carruthers A (1999) Practical cosmetic Botox® techniques. J Cutan Med Surg 3: S49–52

    PubMed  Google Scholar 

  41. Beljaards RC, de Roos KP, Bruins FG (2005) New-Fill for skin augmentation: a new filler or failure? Dermatol Surg 31:772–776; discussion 776

    Article  PubMed  CAS  Google Scholar 

  42. Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systemic review and meta-analysis. Curr Med Res Opin 20:981–990

    Article  PubMed  CAS  Google Scholar 

  43. Hsu TS, Dover JS, Kaminer MS, Arndt KA, Tan MH (2003) Why make patients exercise facial muscles for 4 hours after botulinum toxin treatment? Arch Dermatol 139:948

    Article  PubMed  Google Scholar 

  44. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Morduant J, Walker P, Eadie N; Botox® Glabellar Lines I Study Group (2002) A multi-center, double-blind, randomized, placebo-controlled study of efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46:840–849

    Article  PubMed  Google Scholar 

  45. Fagien S (2004) Temporary management of upper lid ptosis, lid malposition, and eyelid fissure asymmetry with botulinum toxin type A. Plast Reconstr Surg 114:1892–1902

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, AboutSkin Dermatology and DermSurgery, University of Colorado, Denver, Colorado, USA

    Joel L. Cohen

  2. Department of Dermatology, Palm Beach Esthetic Center, University of Miami, Miami, Florida, USA

    Kenneth Beer

Authors
  1. Joel L. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth Beer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. UMDN-New Jersey Medical School, Newark, New Jersey, USA

    David J. Goldberg (Skin Laser and Surgery Specialists of New York and New Jersey) (Skin Laser and Surgery Specialists of New York and New Jersey)

  2. Mount Sinai School of Medicine, New York, New York, USA

    David J. Goldberg (Skin Laser and Surgery Specialists of New York and New Jersey) (Skin Laser and Surgery Specialists of New York and New Jersey)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Cohen, J.L., Beer, K. (2007). Botulinum Toxins. In: Goldberg, D.J. (eds) Facial Rejuvenation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69518-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69518-9_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69517-2

  • Online ISBN: 978-3-540-69518-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation